A Randomized, Double-Blind, Double-Dummy, Active-Comparator, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab Versus MMF in Patients With Pemphigus Vulgaris
Phase of Trial: Phase III
Latest Information Update: 10 Nov 2017
At a glance
- Drugs Rituximab (Primary) ; Mycophenolate mofetil
- Indications Pemphigus vulgaris
- Focus Therapeutic Use
- Acronyms PEMPHIX
- Sponsors Roche
- 16 Mar 2017 Planned End Date changed from 1 May 2019 to 7 Sep 2019.
- 16 Mar 2017 Planned primary completion date changed from 1 May 2019 to 30 Sep 2018.
- 01 Feb 2016 Planned End Date changed from 1 Feb 2019 to 1 May 2019 reported by ClinicalTrials.gov record.